secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000950170-23-021217
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reneo Pharma Q1 net loss $15.1M; STRIDE enrollment complete, topline 4Q23
-------------------------------------------------------------------------

- Net loss of $15.1M ($0.60/sh) vs $13.0M ($0.53) in Q1 2022.
- Cash, equivalents, and short-term investments totaled $93.8M as of March 31, 2023.
- Completed enrollment of pivotal STRIDE study (213 patients); topline results expected Q4 2023.
- Raised $68.3M gross from public offering and private placement in May 2023.
- Received FDA Fast Track designation for mavodelpar in long-chain fatty acid oxidation disorder.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000095017023021217/0000950170-23-021217-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000095017023021217/rphm-20230511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-021217

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer